Joanne Curley - 18 Oct 2022 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Development Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
18 Oct 2022
Net transactions value
-$95,157
Form type
4
Filing time
20 Oct 2022, 16:37:51 UTC
Previous filing
06 Oct 2022
Next filing
10 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $6,870 +1,078 +3.9% $6.37 28,887 18 Oct 2022 Direct
transaction VERA Class A Common Stock Sale $20,946 -1,078 -3.7% $19.43 27,809 18 Oct 2022 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $6,408 +2,212 +8% $2.90* 30,021 18 Oct 2022 Direct
transaction VERA Class A Common Stock Sale $42,883 -2,212 -7.4% $19.39 27,809 18 Oct 2022 Direct F1, F3
transaction VERA Class A Common Stock Options Exercise $58,278 +5,298 +19% $11.00 33,107 18 Oct 2022 Direct
transaction VERA Class A Common Stock Sale $102,865 -5,298 -16% $19.42 27,809 18 Oct 2022 Direct F1, F4
transaction VERA Class A Common Stock Options Exercise $22 +2 +0.01% $11.00 27,811 18 Oct 2022 Direct
transaction VERA Class A Common Stock Sale $40.6 -2 -0.01% $20.30 27,809 18 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -1,078 -9.1% $0.000000 10,795 18 Oct 2022 Class A Common Stock 1,078 $6.37 Direct F5
transaction VERA Stock Option (right to buy) Options Exercise $0 -2,212 -5.2% $0.000000 40,224 18 Oct 2022 Class A Common Stock 2,212 $2.90 Direct F6
transaction VERA Stock Options (right to buy) Options Exercise $0 -5,300 -5.9% $0.000000 84,017 18 Oct 2022 Class A Common Stock 5,300 $11.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.07 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.04 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.93, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter.
F6 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.
F7 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter.